Abstract: IgA nephropathy (IgAN) is the most common primary glomerulonephritis worldwide and the leading cause of endstage renal disease. However, due to the unclear etiology, there is a lack of specific treatment options. Over the past few decades, some progress has been made in understanding the complex pathogenesis of IgAN, which has also promoted the development of targeted therapies. In this review, we will summarise the current possible targeted therapeutic strategies for IgAN, which include targeting the gut mucosal immune system, targeting B cell signalling, targeting the complement system, targeting rapamycin complex 1(mTORC1) to induce autophagy, targeting endothelin1 related receptors, targeting the degradation of galactosedeficient IgA1 (GdIgA1),hope to provide new ideas for finding more effective treatments.